Clinical potential of liraglutide in cardiovascular risk reduction in patients with type 2 diabetes: evidence to date

Clinical potential of liraglutide in cardiovascular risk reduction in patients with type 2 diabetes: evidence to date

Rebecca Howell,1 Adrienne M Wright,1 Jennifer N Clements2 1Presbyterian College School of Pharmacy, Clinton, SC 29325, USA; 2Department of Pharmacy Practice, Presbyterian College School of Pharmacy, Clinton, SC 29325, USA Abstract: Metformin is the first-line therapy for the management of type 2 dia...

Full description

Bibliographic Details
Main Authors:	Howell R, Wright AM, Clements JN
Format:	Article
Language:	English
Published:	Dove Medical Press 2019-04-01
Series:	Diabetes, Metabolic Syndrome and Obesity
Subjects:	glucagon-like peptide-1 glucagon-like peptide-1 receptor agonist liraglutide cardiovascular
Online Access:	https://www.dovepress.com/clinical-potential-of-liraglutide-in-cardiovascular-risk-reduction-in--peer-reviewed-article-DMSO

Similar Items

LIRAGLUTIDE PLEIOTROPIC EFFECT IN CARDIOVASCULAR RISK REDUCTION IN TYPE 2 DIAbETES — A MANDATE FOR CARDIOLOGIST AND INTERNIST
by: S. V. Nedogoda
Published: (2018-05-01)

Liraglutide Attenuates Aortic Valve Calcification in a High-Cholesterol-Diet-Induced Experimental Calcific Aortic Valve Disease Model in Apolipoprotein E-Deficient Mice
by: Yangzhao Zhou, et al.
Published: (2023-09-01)

Gut microbiota mediates positive effects of liraglutide on dyslipidemia in mice fed a high-fat diet
by: Li Zhao, et al.
Published: (2022-12-01)

Short-term monotherapy with Liraglutide for weight management: A case study
by: Feras Almarshad
Published: (2019-01-01)

Efficacy and Safety of Liraglutide and Semaglutide on Weight Loss in People with Obesity or Overweight: A Systematic Review
by: Xie Z, et al.
Published: (2022-12-01)

Liraglutide improved inflammation via mediating IL-23/Th-17 pathway in obese diabetic mice with psoriasiform skin
by: Pin Chen, et al.
Published: (2021-10-01)

Gglucagon-like peptide-1 analogue liraglutide (Saxenda®): mechanism of action, efficacy for the treatment of obesity
by: Tatiana I. Romantsova
Published: (2018-04-01)

Protective effect of GLP-1 analog liraglutide on podocytes in mice with diabetic nephropathy
by: Shaomin Shi, et al.
Published: (2023-09-01)

Liraglutide Accelerates Ischemia‐Induced Angiogenesis in a Murine Diabetic Model
by: Yu‐xin Zhu, et al.
Published: (2023-02-01)

Liraglutide; A New Hope for Obese Diabetics
by: Ajeet Kumar, et al.
Published: (2020-12-01)

Liraglutide in the treatment of heart failure: insight from FIGHT and LIVE
by: Bo Liang, et al.
Published: (2020-07-01)

A randomized trial to investigate the efficacy and safety of once‐daily liraglutide 1.8 mg in Japanese adults with type 2 diabetes exhibiting an inadequate response to liraglutide 0.9 mg
by: Yutaka Seino, et al.
Published: (2022-08-01)

New Insights into the Use of Liraglutide—Impact on Cardiovascular Risk and Microvascular Outcomes
by: Magdalena Wronka, et al.
Published: (2023-04-01)

The benefits of GLP1 receptors in cardiovascular diseases
by: Lamija Ferhatbegović, et al.
Published: (2023-12-01)

GLP-1 receptor agonists in the treatment of type 2 diabetes – state-of-the-art
by: Michael A. Nauck, et al.
Published: (2021-04-01)

Association of glucagon‐like peptide‐1 receptor‐targeted imaging probe with in vivo glucagon‐like peptide‐1 receptor agonist glucose‐lowering effects
by: Takaaki Murakami, et al.
Published: (2020-11-01)

Prediction of early response to liraglutide therapy in patients with obesity
by: Oksana V. Logvinova, et al.
Published: (2020-06-01)

Addendum 2: Forum for Injection Technique, India
by: Sanjay Kalra, et al.
Published: (2014-01-01)

Insulin–glucagon‐like peptide‐1 receptor agonist relay and glucagon‐like peptide‐1 receptor agonist first regimens in individuals with type 2 diabetes: A randomized, open‐label trial study
by: Yumie Takeshita, et al.
Published: (2022-06-01)

Anti-obesity therapy for cardiovascular disease prevention: potential expected roles of glucagon-like peptide-1 receptor agonists
by: Kosuke Sawami, et al.
Published: (2022-09-01)

Efficacy and Safety of the New Appetite Suppressant, Liraglutide: A Meta-Analysis of Randomized Controlled Trials
by: Shinje Moon, et al.
Published: (2021-06-01)

A diabetic patient increased premature ventricular contractions after using liraglutide: a case report
by: Lilan Huang, et al.
Published: (2024-01-01)

Effects of Treatment with Liraglutide Early after Surgical Intervention on Clinical Outcomes in Patients with Short Bowel Syndrome: A Pilot Observational “Real-Life” Study
by: Fabio Dario Merlo, et al.
Published: (2023-06-01)

GLP-1 receptor agonists: A novel pharmacotherapy for binge eating (Binge eating disorder and bulimia nervosa)? A systematic review
by: Laurence Aoun, et al.
Published: (2024-03-01)

Cardiovascular Protection with a Long-Acting GLP-1 Receptor Agonist Liraglutide: An Experimental Update
by: Collin Vandemark, et al.
Published: (2023-02-01)

Liraglutide Attenuates Hepatic Ischemia–Reperfusion Injury by Modulating Macrophage Polarization
by: Shang-Lin Li, et al.
Published: (2022-04-01)

Does combining liraglutide with intragastric balloon insertion improve sustained weight reduction?
by: Mahmoud M Mosli, et al.
Published: (2017-01-01)

Cardiovascular Effects of Glucagon-Like Peptide-1 Receptor Agonists
by: Yu Mi Kang, et al.
Published: (2016-06-01)

Targeting the GLP-1/GLP-1R axis to treat osteoarthritis: A new opportunity?
by: C. Meurot, et al.
Published: (2022-01-01)

Liraglutide improved the reproductive function of obese mice by upregulating the testicular AC3/cAMP/PKA pathway
by: Ruibing Qi, et al.
Published: (2024-03-01)

Future Perspectives on GLP-1 Receptor Agonists and GLP-1/glucagon Receptor Co-agonists in the Treatment of NAFLD
by: Marta Seghieri, et al.
Published: (2018-11-01)

Liraglutide to Improve corONary haemodynamics during Exercise streSS (LIONESS): a double-blind randomised placebo-controlled crossover trial
by: Aung Myat, et al.
Published: (2021-02-01)

Predictors of effectiveness of glucagon-like peptide-1 receptor agonist therapy in patients with type 2 diabetes and obesity
by: Ekaterina V. Tikhonenko, et al.
Published: (2018-12-01)

Efficacy of liraglutide, a glucagon-like peptide-1 (GLP-1) analogue, on body weight, eating behavior, and glycemic control, in Japanese obese type 2 diabetes
by: Fujishima Yuya, et al.
Published: (2012-09-01)

Evaluating the bioequivalence and safety of liraglutide injection versus Victoza® in healthy Chinese subjects: a randomized, open, two-cycle, self-crossover phase I clinical trial
by: Chao Liu, et al.
Published: (2023-12-01)

Use of Liraglutide 3.0 mg for Weight Management in a Real-World Setting in Switzerland
by: Christiane Lundegaard Haase, et al.
Published: (2021-08-01)

The associations of incretin hormone concentration with gestational diabetes mellitus
by: Tatiana V. Saprina, et al.
Published: (2016-05-01)

Fibroblast growth factor-21 is required for weight loss induced by the glucagon-like peptide-1 receptor agonist liraglutide in male mice fed high carbohydrate diets
by: Thao D.V. Le, et al.
Published: (2023-06-01)

The Impact of Glucagon-like Peptide 1 Receptor Agonists on Obstructive Sleep Apnoea: A Scoping Review
by: Khang Duy Ricky Le, et al.
Published: (2024-01-01)

Pharmacokinetics and brain distribution of the therapeutic peptide liraglutide by a novel LC–MS/MS analysis
by: Hyeon Seok Oh, et al.
Published: (2023-03-01)